Form 4: Regeneron Director Craig B. Thompson Reports Stock and Option Transactions

Director Craig B. Thompson reports acquisition of restricted stock units and stock options in Regeneron Pharmaceuticals.

Summary

• Craig B. Thompson, a director of Regeneron Pharmaceuticals, reported transactions involving the company's securities.
• On January 2, 2025, Thompson acquired 166 shares of common stock and 1,958 non-qualified stock options.
• The stock acquisition was through time-based vesting restricted stock units, each representing a contingent right to receive one share of Regeneron's common stock.
• The exercise price of the non-qualified stock options is $719.37.
• A portion of the stock options will become exercisable on the date of the Issuer's first annual meeting of shareholders following the date of grant, equal to the portion of one year that has passed from the date of grant, and the remainder shall become exercisable on the first anniversary of the date of grant.
• The options expire on January 2, 2035.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of insider transactions. The acquisitions could be interpreted positively, but it's not definitive.

Positives

• The acquisition of stock and options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.

Stakeholder Impact

• The transactions may have a minor impact on shareholders' perception of the company, depending on how they interpret the director's actions.

Key Dates